Cantor Fitzgerald Predicts RARE FY2026 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will post earnings per share of ($2.61) for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $118.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share.

Several other equities analysts have also weighed in on the stock. William Blair began coverage on shares of Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 target price on the stock. Piper Sandler reduced their price objective on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Monday, March 17th. JPMorgan Chase & Co. boosted their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Canaccord Genuity Group increased their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th. Finally, Morgan Stanley boosted their price objective on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of "Moderate Buy" and an average target price of $88.77.

Ultragenyx Pharmaceutical Stock Up 4.7%

Shares of Ultragenyx Pharmaceutical stock traded up $1.78 during trading hours on Tuesday, reaching $39.29. 1,919,627 shares of the company's stock were exchanged, compared to its average volume of 857,921. The business has a fifty day moving average of $35.77 and a two-hundred day moving average of $40.20. The company has a market capitalization of $3.71 billion, a P/E ratio of -6.20 and a beta of 0.25. Ultragenyx Pharmaceutical has a 1 year low of $29.59 and a 1 year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). The business had revenue of $139.29 million for the quarter, compared to analysts' expectations of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The business's revenue for the quarter was up 28.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($2.03) EPS.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Ultragenyx Pharmaceutical by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company's stock worth $422,167,000 after buying an additional 89,389 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Ultragenyx Pharmaceutical by 28.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company's stock valued at $116,559,000 after purchasing an additional 706,519 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Ultragenyx Pharmaceutical by 81.6% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company's stock worth $77,815,000 after acquiring an additional 965,919 shares during the last quarter. Federated Hermes Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 0.3% in the first quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company's stock worth $74,419,000 after acquiring an additional 5,400 shares during the last quarter. Finally, Deutsche Bank AG grew its holdings in Ultragenyx Pharmaceutical by 0.5% in the first quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company's stock valued at $61,611,000 after purchasing an additional 8,385 shares during the period. Institutional investors and hedge funds own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.